Welcome to our dedicated page for Gilead Sciences SEC filings (Ticker: GILD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking Gilead’s science is only half the battle—decoding its SEC paperwork is the other. Each 10-K can exceed 250 pages of antiviral sales data, oncology trial risk factors, and patent-expiry timelines that impact Biktarvy’s future cash flows. Add surprise 8-K material events on FDA outcomes and dozens of Form 4 insider trades from researchers at Kite Pharma, and the disclosure maze grows fast.
Stock Titan’s AI resolves that complexity. Our platform streams every Gilead Sciences SEC filing the moment it hits EDGAR and delivers plain-English summaries that pinpoint what matters: a spike in R&D spend called out in the latest "Gilead Sciences quarterly earnings report 10-Q filing," a newly granted patent buried in an exhibit, or fresh "Gilead Sciences insider trading Form 4 transactions" that hint at management’s sentiment. Interactive highlights explain cash-flow sensitivities, collaboration milestones, and CAR-T manufacturing risks so you understand "Gilead Sciences SEC filings explained simply" instead of parsing dense legal text.
Use cases include:
- Setting real-time alerts for "Gilead Sciences Form 4 insider transactions" before pivotal trial readouts.
- Comparing segment revenue across HIV, hepatitis C, and oncology lines straight from 10-Q tables.
- Reviewing "Gilead Sciences proxy statement executive compensation" to evaluate R&D incentive alignment.
- Scanning "Gilead Sciences 8-K material events explained" for FDA complete-response letters.
- Reading a "Gilead Sciences annual report 10-K simplified" summary that flags looming patent cliffs.
Whether you’re modelling drug royalties, monitoring "Gilead Sciences executive stock transactions Form 4," or just learning "understanding Gilead Sciences SEC documents with AI," our coverage gives you every filing—and the context—to make informed decisions in minutes, not hours.
Johanna Mercier, Chief Commercial Officer of Gilead Sciences (GILD), reported multiple transactions on 08/15/2025 executed under a Rule 10b5-1 trading plan adopted Feb 20, 2025. The filing shows a series of option-related acquisitions and open-market sales in common stock: total reported sales on that date equal 28,000 shares at prices ranging roughly from $117.91 to $119.01, and multiple option exercises/acquisitions at an exercise price of $66.64. Following the reported transactions, the filing lists beneficial ownership levels of common stock as low as 114,168 shares and various counts of options/derivatives remaining outstanding. The Form 4 also discloses that the related options have a four-year vesting schedule with 25% vesting after one year and the remainder vesting quarterly thereafter.
Andrew D. Dickinson, Chief Financial Officer of Gilead Sciences (GILD), reported an insider sale on Form 4. The filing shows a sale of 2,500 shares of Gilead common stock on 08/15/2025 at a price of $118.53 per share, leaving Mr. Dickinson with 160,110 shares beneficially owned after the transaction. The sale was made pursuant to a Rule 10b5-1 trading plan adopted on 08/29/2024. The Form 4 was signed by Edward S. Son by power of attorney for Mr. Dickinson and dated 08/18/2025.
Form 144 filing for Gilead Sciences (GILD) shows an insider intends to sell 2,500 common shares through Morgan Stanley Smith Barney on 08/15/2025, with an aggregate market value of $296,325 and the shares listed for sale on NASDAQ. The filing identifies prior acquisitions of the shares as restricted stock granted on 03/10/2024 (1,200 shares) and 03/10/2023 (1,300 shares). The notice also lists sales by the same person during the past three months totaling 5,000 shares with aggregate cash proceeds of approximately $553,000. The filer signs a representation that they are not aware of undisclosed material adverse information about the issuer.
Gilead Sciences insider notice for proposed Rule 144 sale. The filing reports a proposed sale of 28,000 common shares through Morgan Stanley Smith Barney, with an aggregate market value of $3,318,924.65 and the company’s outstanding shares listed as 1,240,806,916. The filer shows recent acquisitions including a 25,000-share stock option exercise dated 08/15/2025, 2,394 performance shares (01/31/2024) and 606 restricted shares (12/10/2023). The form also lists multiple dispositions by Johanna Mercier in the past three months, with individual sales and gross proceeds disclosed for each trade.
FAQ
What is the current stock price of Gilead Sciences (GILD)?
What is the market cap of Gilead Sciences (GILD)?
